FDA Extends Deadline for Decision on Ipilimumab

The U.S Food and Drug Administration (FDA) extended its deadline for an approval decision on Bristol-Myers Squibb’s (BMS) drug for advanced melanoma, ipilimumab.  The FDA was expected to reach a decision by December 25, 2010 but has delayed it to March 26, 2011 to give regulators more time to review data on the medicine.